White Paper

Can Yeast Be The Future Of Large Scale And Efficient Subunit Vaccine Manufacturing?

Source: Lonza

By Lisa Yu and Devarshi Kapadia

GettyImages-1307578388-Pichia pastoris yeast

Vaccines have been developed at record breaking speeds to fight the COVID-19 pandemic and are already saving lives1. At the time of writing, over 2.55 billion COVID-19 vaccine2 doses have been administered globally and are paving the way to a return to a "new normal." However, there is still a pressing need to develop more vaccine options to further increase global access, and prepare for future infectious disease challenges. To aid in the manufacturing of new vaccines, Pichia pastoris yeast, a promising protein expression system, could be the perfect solution.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online